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Abstract
Barrett's oesophagus, which is thought to be a consequence of gastro-oesophageal reflux disease
(GORD), is a well-recognized precursor of oesophageal adenocarcinoma. Medical therapies and anti-
reflux surgeries for GORD have shown conflicting results regarding the progression of Barrett's
metaplasia to neoplasia. After high-grade dysplasia or intramucosal cancer is identified, it has been
standard practice to conduct an oesophagectomy, despite this having an associated risk of morbidity
and mortality. In recent years however, endoscopic therapy has become a viable alternative to
oesophagectomy in treating early neoplasia.
Introduction and context
Barrett's oesophagus (BO) is characterized by replacing
the distal oesophageal squamous mucosa with columnar
epithelium containing specialized intestinal metaplasia
(IM). The metaplastic epithelium accumulates genetic
changes over a period of time and can progress to
dysplasia and cancer. These patients carry a cancer risk
that is 30 to 125 times more than that of an age-matched
population [1]. Screening for BO remains controversial,
but regular surveillance is a standard practice once IM is
identified. Guidelines set out by The American College
of Gastroenterology, as well as those of several other
national gastrointestinal societies, suggest that quadran-
tic biopsies should be conducted every 2 cm of BO
during surveillance. However, with recent advanced
imaging techniques such as autofluoroscence and
narrow band imaging, biopsies can be targeted with
good yield to detect early neoplasia [2].
Medical management
The main aim of treatment in BO is to control reflux
symptoms and prevent the development of dysplasia
and cancer. Medical therapies are mainly directed toward
controlling gastro-oesophageal reflux disease. H2-recep-
tor antagonists have shown benefits in controlling
symptoms of BO but have not shown regression in the
length of metaplastic epithelium [3]. Similarly, proton-
pump inhibitors (PPIs) are useful in treating oesopha-
gitis associated with BO, but there is no consistent
evidence to suggest significant regression of disease or
benefits in preventing the development of neoplasia.
Control of reflux symptoms by PPIs does not necessarily
equate with complete inhibition of acid reflux and some
patients can have bile reflux, which is known to influence
the development and persistence of metaplastic epithe-
lium. An increase in squamous islands is noted after PPI
use, but studies show that IM is often present underneath
those islands [4].
Chemoprevention measures using non-steroidal anti-
inflammatory drugs and aspirin in BO have shown some
benefits in preventing the development of neoplasia [5].
However, results from the recent Chemoprevention for
Barrett's Esophagus Trial (CBET) were disappointing
with regard to the use of celecoxib [6]. Ongoing trials
like the Aspirin Esomeprazole Chemoprevention Trial
(AspECT) will throw light on to the role of aspirin in
preventing Barrett's associated cancer of the oesophagus.
Surgical management
Laparoscopic anti-reflux surgeries like fundoplication
have the benefit of controlling acid and bile reflux better
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development of cancer in BO is conflicting. Some studies
have shown a progression to cancer in spite of surgery
and there is no consistent evidence to suggest the
regression of Barrett's mucosa following surgery [7].
Once high-grade dysplasia is identified, oesophagectomy
has been the standard practice, however newer endother-
apeutic techniques are now capable of treating dysplasia
and early cancer, thereby avoiding major surgery.
Endoscopic ablation techniques
Argon plasma coagulation (APC) uses an ionized
electrically conducting argon beam that delivers a high
local temperature of 130°C leading to desiccation of
tissue to a maximum depth of 3 to 4 mm, which is ideal
to destroy the metaplastic epithelium [8]. Many studies
involving APC have shown benefits of eradication of
Barrett's mucosa and early neoplasia with restoration of
squamous epithelium [8,9]. Multipolar electrocoagula-
tion using a gold probe has been shown to be equally
effective, with up to 70% of patients showing a complete
reversal of Barrett's epithelium [10]. Unlike these
techniques, photodynamic therapy (PDT) involves a
non-thermal chemical process using a photosensitizing
drug that can be given intravenously, orally or topically.
The drug concentrates in the metaplastic and dysplastic
epithelium and is sensitized by a bright light of
appropriate wavelength to facilitate tissue necrosis. The
main advantage of this technique is that larger areas can
be uniformlytreated with asingle treatment session. PDT
was found to be equally effective as APC in ablating
Barrett's mucosa but more effective in eradicating
dysplasia [8,11]. Oesophageal stricture and photosensi-
tization are reported following the above techniques.
Currently, there is insufficient evidence to support the
use of these techniques in non-dysplastic IM.
Endoscopic resection techniques
Endoscopic mucosal resection (EMR) is an alternative
technique to ablation in which the neoplastic epithelium
is resected rather than ablated and hence gives a
definitive histological diagnosis and potential cure. It
can also be effectively used in the treatment of
intramucosal cancer [12,13]. The EMR cap technique
uses a transparent cap attached to the endoscope, which
allows suction of the abnormal mucosa into the cap after
submucosal injection of adrenaline. This can be resected
using a snare and electrocoagulation [14]. Alternatively,
oesophageal variceal ligation bands can be applied to the
area of interest, followed by resection with a snare after
removing the banding device. This is known as the ‘suck-
band-and-cut’ technique [12]. No significant difference
in the diameter of resected specimens, or in complica-
tions, was observed between these two techniques. Flat
Barrett's neoplasia can also be removed using a mono-
filament polypectomy snare without the use of any
submucosal lifting or additional devices [15]. Minor
bleeding can occur in up to 10% of cases after EMR, but
major complications such as perforation and strictures
are rare.
Recent advances
En bloc dissection of large neoplastic lesions using a
specially designed needle knife has been attempted by
Japanese endoscopists, but this necessitates expertise.
A multiband mucosectomy device (Duette; Cook Endo-
scopy, Winston-Salem, NC, USA, formerly Wilson-Cook
Medical Inc), which allows resection of multiple areas
using a technique like variceal banding ligation, is now
commercially available. Unlike the suck-band-and-cut
technique, it does not need a withdrawal of the scope
between resections.
A newer technique of radiofrequency ablation (RFA)
using a specially designed balloon known as the BÂRRX
HALO system is available to ablate the neoplastic
epithelium. Any visible abnormalities in the neoplastic
mucosa are removed by EMR prior to RFA (Figure 1).
HALO
360containsmultipleelectrodesencirclingtheouter
surface of the balloon and can be used for circumferential
ablation. Any residual Barrett's epithelium can be
Figure 1.
(a) High-resolution white-light image of Barrett's oesophagus with subtle
irregular mucosa at the 5 o'clock position, (b) autofluorescence imaging
revealing an abnormal signal between the 2 and the 7 o'clock positions,
(c) multiband mucosectomy (Duette) endoscopic mucosal resection,
(d) pathology showing intramucosal adenocarcinoma without submucosal
invasion, (e) HALO
360 radiofrequency ablation of remaining Barrett's
epithelium, and (f) post-ablation squamous regeneration.
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90 system.
Initial reports suggest complete remission in dysplasia
and Barrett's mucosa using this technique [16,17]. The
incidence of residual dysplasia, oesophageal stenosis and
buried Barrett's mucosa was reported to be less with RFA
circumferential ablation compared with other ablative
techniques.
Implications for clinical practice
Regular systematic surveillance of BO is warranted in the
absence of any definitive measures available to prevent
progression of disease. Endoscopic therapy for early
neoplasia in BO is promising, but the ideal method is yet
to be decided. EMR followed by RFA seems most
promising. Patients with Barrett's neoplasia should
ideally be treated in a dedicated centre with the help of
a committed multidisciplinary team.
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